Surgery to remove liver metastases is an accepted treatment modality in patients with colorectal cancer (22). Its role in breast cancer is, however, much less recognized. Liver is a common metastatic breast cancer site, but only 5% of patients have isolated liver involvement. In various series of hepatic resection for breast cancer metastases, the reported median survival ranged from 14.5 to 63 months and the 5-year survival from 14% to 61%, in general, comparing well with nonsurgically treated patients. Most of the reported series, however, describe extremely selected patients, constituting 1% or less of metastatic breast cancer patients treated over the respective periods of time (22-26). As an example, in the one of the important series, all patients were asymptomatic and identified through intensive surveillance programs (27). Patients with isolated liver metastasis can potentially be managed with local treatments (surgery, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radiosurgery). In contrast to liver colorectal metastases, local treatment for breast cancer liver metastasis is not considered a therapeutic option due to common involvement of additional organs; nevertheless, in some selected patients, local approaches have been associated with long-term survival (10,29,30).